Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice buy. I'd wager that's gotta be a fund loading up. Of course there's a seller too. Maybe our friend Nomis shaving a few off here.
Here you go. PROOF that Aviptadil acts as a potent suppressor of inflammation in vivo by trans-deactivating chemokine receptors!!!
https://pubmed.ncbi.nlm.nih.gov/14607894/
"We show that VIP inhibited the function of chemokine receptors on monocytes and CD4(+) T lymphocytes, with impaired chemotaxis and calcium flux in response to the cognate chemokine ligands CXCL12, CCL3, CCL4, and CCL5. This was mediated by VIP receptor type 1 and was not caused by chemokine receptor internalization. However, VIP caused dose-dependent phosphorylation of the chemokine receptor CCR5. "
What you might not realize is that there is published data showing that Aviptadil blocks many CCXXs, including CCL5 (RANTES). As known to most of the folks in this space now, Leronlimab's MOA is attaching to the CCR5 receptor and blocking CCL5. Knowing that further evidence points to Aviptadil's MOA is a great thing and useful information. Elonmarx's posts give further credence to Aviptadil and that is why I appreciate them.
It's not "dummy" science and its not a TOS violation to discuss another therapeutic agent with a similar target MOA. Please stop overreacting to rational and informed posts by knowledgeable posters.
Just making a play on words. Maybe American puns don't go over well in France. I'll pay you back for the awful DUCK pun. You can put it on my BILL.
You said "The duck test is a form of abductive reasoning." Now didn't you mean abDUCKtive reasoning???
Many countries in UK, Australia, Europe in general have a very large number of outstanding shares. It is quite common. Sometimes there will be a U.S. traded ADR that will be 100 to 1 -- every 1 ADR share is valued at 100 shares of the home country stock.
In these situations, I look at market cap. It doesn't remove the issue entirely, but when you see that large shareholders and insiders own about 50% of the common stock of RLFTF, it means that we are in the same boat. Which is a good thing.
Example: Mesoblast has a US traded ADR at $18.50 per share U.S. but 600 million shares out in Australia.
Stop saying 35%. Convalescent Plasma is far less than 35%. That number is a misinterpretation of statistics. See my last post.
RLF-100 appears to be 90%+ effective in critical patients in the consecutive expanded access cases. This is a fact.
Even worse than that, per somebody experienced with statistics. It is far from 35% even:
Holy hell, FDA Commissioner Stephen Hahn's grasp of statistics is alarming. A 35% reduction in mortality does NOT mean that if 100 people get covid-19 and are treated with convalescent plasma, then 35 lives will be saved.
— Susan Simpson (@TheViewFromLL2) August 23, 2020
Even worse than that, per somebody experienced with statistics.
Holy hell, FDA Commissioner Stephen Hahn's grasp of statistics is alarming. A 35% reduction in mortality does NOT mean that if 100 people get covid-19 and are treated with convalescent plasma, then 35 lives will be saved.
— Susan Simpson (@TheViewFromLL2) August 23, 2020
Great information about production processes. Thanks Jama87 for your contributions to the discussion.
Very important piece of information to consider. Republican congressman Harris is an MD and one of the three members of the DMC. He will have direct and detailed knowledge of how the study is going.
They weren't PATENTS! They are TRADEMARK filings! Learn the damn difference please. RELIEF THERAPEUTICS owns all the patents to RLF-100/Samivir.
Still early days with regards to Captain Searcy. Third day of treatment was only today I believe. Looking at the ECMO patients in the extended access report, it can take many days until a clear response is seen. Patients on ECMO are extremely critical as we know. ECMO itself is a Hail Mary.
Please let's continue to provide valuable information and show appreciation for valued posters. Public messages about individual posters are subject to removal per the Moderator Handbook. Best to focus on the company and the stock.
Everybody concerned about reverse splits take note:
Relief Therapeutics, should they want to uplist to NASDAQ etc., will not need to do a reverse split! Because they can choose to list as an ADR. An ADR is an "American Depository Receipt". It represents a share in the foreign listed company in whatever ratio they want.
So it could be 1 ADR equals 20 shares, 1 ADR equals 100 shares, or 1 ADR equals 1000 shares.
So, if you hold 1 share of Relief ADRs, listed on NASDAQ, that represents 100 shares of Relief Therapeutics on the Swiss Exchange.
At a ratio of 1 to 100, with Relief Therapeutics on the Swiss Exchange at .60 Swiss francs, the share price of the ADRs on the NASDAQ would be $66 per share. (Swiss francs are trading at 1.10 to $1 US dollar)
Problem solved.
Absolutely correct. In many countries outside the U.S., such as Australia and the U.K., it is extremely common for well regarded companies to have a huge outstanding share count and a low single digit stock price. Those countries understand it is all about market cap. They are not as big on reverse splits apparently. They rely on people's ability to figure out market capitalization.
With the amazing results RLFTF's RLF-100 has shown so far, I think we will see approval for sure. I think that will equate to AT LEAST a $10 Billion market cap.
Relief Therapeutics and NeuroRx are going to be starting a clinical trial with RLF-100 using a nebulizer in a week: https://clinicaltrials.gov/ct2/show/NCT04360096?term=aviptadil&draw=2&rank=2
The nebulizer is very similar to a vape device, except for the important fact that it does not require additives like glycerin and propylene glycol, which is not a good thing for patients on ventilators. Nebulizers use compressed air or oxygen to break the medication into an aerosol mist for inhalation into the lungs.
The trial will have the patients take RLF-100 3 times a day with a nebulizer.
Should absolutely work, according to NeuroRx, especially for patients who are not too sick, since those patients lungs are less able to take up the medicine. That is why they are doing systemic IV infusions for the sickest patients right now.
Thanks for posting this rockytoad. Please continue to update us on anything you find, and I'll do the same. All these pieces of information coming from various sources keep validating Aviptadil as the best Covid-19 defense that I've yet seen.
I believe is says:
"I think we will move forward with them...[in some...in some capacity.]"
A potential partner wouldn't give a damn about how many shares Relief Therapeutics has outstanding, or about whether Relief Therapeutics is a public company, or where it trades if so.
A potential partner only cares about getting the rights to RLF-100.
NeuroRx is carrying the ball in the U.S. and potentially elsewhere. Relief Therapeutics will just be depositing the upfront payments, license fees and royalty payments.
As more case studies, trials, and approvals come to light, Relief will shine more and more. More investors will come into the stock. The stock will rise.
The preprint paper is an amazing document. RLF-100 works (to be confirmed by double-blinded placebo controlled studies.)
Based on the trading right now, 8:40am Pacific, I predict we are about to go up.
As predicted! See this Form 4 for Samir Patel. Grant of 225,000 options. No shares listed, just like Welch's Form 4. Filled out and filed by the same attorney on their behalf.
https://www.sec.gov/Archives/edgar/data/1175680/000180709420000012/xslF345X03/primary_doc.xml
Yet, the Def 14A shows that Samir Patel owned 9,531,203 shares as of May 28, 2020.
https://www.sec.gov/Archives/edgar/data/1175680/000119312520174344/d933854ddef14a.htm
If either of them sold shares, they would have needed to submit a filing to that effect. They are directors of the company.
They didn't submit a filing. Ergo, they didn't sell shares.
DEBUNKED.
Welch held 15,560,773 shares(4) as of May 28, 2020.
(4) Includes: (i) 9,513,417 shares of Common Stock, 1,000 shares of Series D Convertible Preferred Stock convertible into 1,250,000 shares of Common Stock and a warrant covering 500,000 shares of Common Stock held by a limited liability company for which Dr. Welch is the managing member and has voting and dispositive power; (ii) 3,002,202 shares of Common Stock held directly by a trust for which Dr. Welch, as trustee, has voting and dispositive power; and (iii) 1,295,154 shares of Common Stock subject to options held directly by Dr. Welch.
https://www.sec.gov/Archives/edgar/data/1175680/000119312520174344/d933854ddef14a.htm
The close today will be something to behold. I think we will end up at .802.
Congratulations to you as well. Let us know what the chatter is from the scientific community in Europe. Relief is going to be the talk of the town.
YES, very very important. Not cherry picked patients and the sickest of the sick! THE FIRST 21 CONSECUTIVE patients. They didn't pick the people they thought would do better. They just took everybody who came in the door and was too sick to even be in the clinical trial.
Amazing results. This is going to be a big victory for the world and for stockholders.
It was up to NeuroRx and Relief to allow for the administration of RLF-100 to Cap. Searcy. They did so immediately. However, Houston Methodist did provide the medicine, and one of their doctors who is working with Covid patients at Houston Methodist is I believe consulting with the Memorial Hermann doctor in charge of Cap. Searcy's care.
Terrific pegs1! Thanks for sharing your experience. So happy to hear that your lung disease has been kept at bay all these years with Aviptadil. Does the disease have a formal name? I'd like to research more about it.
Millstone
tiggerifficm4, thank you for bringing the news about Captain Searcy to this board's attention. I hope everybody on this board is pulling for him. I can't imagine the lack of compassion and respect that some can demonstrate.
Great news! Great find!
https://dhrresearch.org
This is DHR Research in Texas. Now approved to give Aviptadil as well according to the Expanded Access protocol.
The stock already filled the "gap" at .581. The gap was not at .54.
Do you know what a trademark is? Do you know what a patent is? Start with finding out the answers to these two questions. The filing that has been posted is a TRADEMARK! RELIEF owns the drug patent! The trademark is for NeuroRx to market in the U.S.
Come on, use your brain. NeuroRX is the U.S. partner, who Relief is using to progress RLF-100 through trials. NeuroRX is applying for trademarks for use of RLF-100 in the U.S. once FDA approved.
Understand that CYDY intends to uplist come hell or high water. They realize the importance of a NASDAQ listing. They must cover any possibilities in their SEC filings. Shorts will try to knock them under so they don't meet stock price listing standards, but it is essentially restraint of trade and illegal market manipulation (if anybody cared to monitor).
Listing on NASDAQ, contrary to the shorts' hysterical screaming, is not actually hard. It is solely a matter of meeting the criteria and filing the paperwork correctly. It is not like joining Skull and Bones at Yale or any other freaking secret society. If they meet the criteria, they will uplist.
I have owned many many stocks that have uplisted: CTSO, AVXL, ABAXIS (sure should have held that one, which I owned at 3 and it got taken out at $83), STXS (to NYSEAmerican).
Eventually, the shorts will move on once they feel that there are better targets. In fact, I think that time is now, which is why they are trying to lower the price to get out. Shorts are a calculating bunch. They don't like to overstay their welcome.
PITrader87 I think you are spot on about non qualified stock options. My recollections from having them in the past track exactly what you wrote. A low stock price when exercised is key, because you are taxed on that stock price at exercise whether you sell right then or not!
Seems to me like a good price to buy more and average up at $3.37.
Why?
1. Technically speaking, the stock is VERY oversold. It can stay that way for a while, yes, but historically speaking it has not.
2. Short attacks and attacks from AF: Hitting a fever pitch. Usually this occurs when they are looking to cover the short position because of impending news that will be favorable toward a company. I think in this case they believe that CYDY is about to become NASDAQ listed, and/or they might get a favorable ruling from the FDA about EUA.
A hallmark of short desperation is inaccurate information. There is enough out there that can make one skittish about investing in CYDY. In balance, the positives have outweighed the negatives though, so the shorts and their mouthpieces have resorted to misleading information (such as imminent financial trouble) which is clearly refutable.
An aside: To me, a journalist with a bias contacting various customers, patients, and clinicians trying to convince them that CytoDyn is not on the up and up is essentially restraint of trade and should be actionable in the courts.
Edit: AF tweeted his latest article and disabled the ability to comment on it. That speaks chapters about its defensibility.
That is very classy indeed. Honoring the doctor who discovered VIP and spent his life researching it.
The previous trial exclusion criteria was people over 85 years old. It did NOT exclude elderly people. Unless people 65-84 years old are not defined as elderly. Average age of mortality is low 70s right? I think 65-84 is elderly. No offense to anybody in that age range or above. Just being precise with language, unlike some!
I expect we'll see a trial update on ClinicalTrials.gov fairly soon. Should provide a lot of tantalizing new information, such as the trial sites.
I'm going to research the cost of product. I've read that cost is moderate compared to other treatments. Will be excellent if this is the case. RLFTF has patent and proprietary formulation. Now an inhaled formulation.
https://clinicaltrials.gov/ct2/show/NCT04360096